Valbenazine was the first of the vesicular monoamine transporter inhibitors to be approved for the treatment of tardive dyskinesia (TD) in 2017.

Trihexyphenidyl is an anticholinergic medication that is less favored than benztropine because it must be dosed three times daily and is only available in oral formulations. 

Tetrabenazine was the original vesicular monoamine transporter inhibitor brought to market and approved for the treatment of Huntington’s disease. 

Metformin is a medication for type 2 diabetes that increases insulin sensitivity and decreases appetite. 

Deutetrabenazine was the second of the vesicular monoamine transporter inhibitors to be approved for the treatment of tardive dyskinesia (TD) in 2017.

Benztropine is an anticholinergic medication that is the go-to agent for treating and preventing antipsychotic-induced extrapyramidal symptoms (EPS).

Amantadine is a dopaminergic medication used primarily in Parkinson’s disease, but it is also helpful in drug-induced parkinsonism and has fewer anticholinergic side effects (eg, cognitive impairment, dry mouth, constipation) than other meds used to combat extrapyramidal symptoms (EPS), like benztropine.

Vardenafil has similar efficacy to other phosphodiesterase type 5 (PDE-5) inhibitors.

Successful marketing has convinced the public that “low T” is a public health scourge, leading to overprescribing of testosterone for patients who don’t need it. Prescribe it only for men with demonstrably low testosterone levels and accompanying symptoms.